DeepMed Research

H. Lee Moffitt Cancer Center and Research Institute, Inc.

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Varenicline Effects on Cue Reactivity and Smoking Reward/Reinforcement

Not Applicable

Completed

Conditions: Tobacco Dependence

Interventions: Drug: placebo
Drug: varenicline

First Posted Date: 2008-09-05

Last Posted Date: 2013-12-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 163

Registration Number: NCT00747643

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Support for People Undergoing Chemotherapy

Not Applicable

Completed

Conditions: Quality of Life
Cancer

Interventions: Behavioral: Usual care
Behavioral: Stress Management training
Behavioral: Exercise Training
Behavioral: Combined stress management and exercise training

First Posted Date: 2008-08-22

Last Posted Date: 2017-02-23

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 471

Registration Number: NCT00740038

Locations: 🇺🇸
Moffitt Cancer Center, Tampa, Florida, United States

Phase I Study of LBH589 & Erlotinib for Advanced Aerodigestive Tract Cancers

Phase 1

Completed

Conditions: Lung Cancer
Head and Neck Cancer

Interventions: Drug: Panobinostat (LBH589)
Drug: erlotinib

First Posted Date: 2008-08-20

Last Posted Date: 2015-02-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 44

Registration Number: NCT00738751

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Visilizumab for the Prevention of Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation

Phase 2

Terminated

Conditions: Graft Versus Host Disease

Interventions: Drug: Visilizumab
Drug: Antithymocyte globulin (ATG)
Drug: Tacrolimus
Drug: Methotrexate

First Posted Date: 2008-07-23

Last Posted Date: 2014-07-18

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 8

Registration Number: NCT00720629

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Genomic Directed Salvage Chemotherapy With Either Liposomal Doxorubicin Or Topotecan

Not Applicable

Terminated

Conditions: Ovarian Cancer

Interventions: Drug: Liposomal Doxorubicin
Drug: Topotecan

First Posted Date: 2008-07-22

Last Posted Date: 2018-01-02

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 4

Registration Number: NCT00720096

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

PSMA and TARP Peptide Vaccine With Poly IC-LC Adjuvant in HLA-A2 (+) Patients With Elevated PSA After Initial Definitive Treatment

Not Applicable

Completed

Conditions: Prostate Cancer

Interventions: Biological: Peptide Vaccine
Drug: Poly IC-LC

First Posted Date: 2008-06-10

Last Posted Date: 2019-10-04

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 29

Registration Number: NCT00694551

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States
🇵🇷
Ponce School of Medicine, Ponce, Puerto Rico

Cetuximab Plus Conformal Thoracic Radiotherapy in Patients (Pts) With Inoperable or Unresectable Locally Advanced Non-Small Cell Lung Cancer (LA - NSCLC)

Phase 2

Completed

Conditions: Lung Cancer

Interventions: Drug: Cetuximab
Radiation: Conformal Thoracic Radiotherapy (CTRT)

First Posted Date: 2008-05-07

Last Posted Date: 2015-10-08

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 27

Registration Number: NCT00673738

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Pilot Trial of a WT-1 Analog Peptide Vaccine in Patients With Myeloid Neoplasms

Not Applicable

Completed

Conditions: Leukemia

Interventions: Biological: WT-1
Drug: Montanide
Drug: Sargramostim (GM-CSF)

First Posted Date: 2008-04-23

Last Posted Date: 2015-02-27

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 16

Registration Number: NCT00665002

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

Pre-Transplant 5-Azacitidine In Patients With High-Risk Myelodysplastic Syndrome Who Are Candidates For Allogeneic Hematopoietic Cell Transplant

Not Applicable

Completed

Conditions: Leukemia

Interventions: Drug: 5-azacitidine
Procedure: Allogeneic Hematopoietic Cell Transplantation (HCT)

First Posted Date: 2008-04-17

Last Posted Date: 2014-09-22

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 25

Registration Number: NCT00660400

Locations: 🇺🇸
H. Lee Moffitt Cancer Center & Research Institute, Tampa, Florida, United States

Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts

Not Applicable

Completed

Conditions: Myelodysplastic Syndromes

Interventions: Drug: Dasatinib

First Posted Date: 2008-02-27

Last Posted Date: 2013-12-16

Lead Sponsor: H. Lee Moffitt Cancer Center and Research Institute

Target Recruit Count: 18

Registration Number: NCT00624585

Locations: 🇺🇸
H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy